Modulation of the Specificity of Carbapenems and Diazabicyclooctanes for Selective Activity against Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

Modulation of the Specificity of Carbapenems and Diazabicyclooctanes for Selective Activity against Mycobacterium tuberculosis

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Barnier Jean-Philippe¹²³,Saidjalolov Saidbakhrom⁴,Bouchet Flavie⁴,Mayer Louis¹,Edoo Zainab¹,Sayah Inès¹,Iannazzo Laura⁴,Ethève-Quelquejeu Mélanie⁴,Mainardi Jean-Luc¹²³,Braud Emmanuelle⁴,Arthur Michel¹^ORCID

Affiliation:

1. INSERM UMR-S 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris, France

2. Université Paris Cité, Faculté de Santé, UFR de Médecine, Paris, France

3. Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Centre-Université Paris Cité, Paris, France

4. Université Paris Cité, CNRS UMR 8601, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Paris, France

Abstract

Treatment of multidrug-resistant tuberculosis with combinations of carbapenems and β-lactamase inhibitors carries risks for dysbiosis and for the development of resistances in the intestinal microbiota. Using Escherichia coli producing carbapenemase KPC-2 as a model, we show that carbapenems can be modified to obtain drugs that are inactive against E. coli but retain antitubercular activity.

Funder

Agence Nationale de la Recherche

Ministère de l'Education Nationale, de l'Enseignement Superieur et de la Recherche

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02357-21

Reference30 articles.

1. WHO. 2020. Global tuberculosis report 2020. WHO, Geneva, Switzerland.

2. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

3. Irreversible Inhibition of the Mycobacterium tuberculosis β-Lactamase by Clavulanate

4. Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

5. β-Lactams against Tuberculosis — New Trick for an Old Dog?

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disseminated tuberculosis in a child during the COVID-19 pandemic: a case report and literature review;Frontiers in Immunology;2023-09-14